Design and synthesis of a novel class of dual PPARgamma/delta agonists

  • Bioorg Med Chem Lett. 2007 Feb 15;17(4):1052-5. doi: 10.1016/j.bmcl.2006.11.029.
Isabel C Gonzalez  1 ,  Jason Lamar ,  Fatima Iradier ,  Yanping Xu ,  Leonard L Winneroski ,  Jeremy York ,  Nathan Yumibe ,  Richard Zink ,  Chahrzad Montrose-Rafizadeh ,  Gary J Etgen ,  Carol L Broderick ,  Brian A Oldham ,  Nathan Mantlo
Affiliations
  • 1. Lilly Research Laboratories, A Division of Eli Lilly & Company, Lilly Corporate center, Indianapolis, IN 46285, USA. [email protected]
PMID: 17129725 DOI: 10.1016/j.bmcl.2006.11.029
Abstract

The design and synthesis of dual PPAR gamma/delta agonist (R)-3-{2-ethyl-4-[3-(4-ethyl-2-pyridin-2-yl-phenoxy)-butoxy]-phenyl}propionic acid is described. This compound dose-dependently lowered plasma glucose in hyperglycemic male Zucker diabetic fatty (ZDF) rats and produced less weight gain relative to rosiglitazone at an equivalent level of glucose control.